This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BridgeBio Pharma (BBIO) and Guardant Health (GH)

Tipranks - Tipranks - Thu Jun 18, 6:06AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on IQVIA Holdings (IQV), BridgeBio Pharma (BBIO) and Guardant Health (GH).

Claim 55% Off TipRanks

IQVIA Holdings (IQV)

In a report released today, Kallum Titchmarsh from Morgan Stanley downgraded IQVIA Holdings to Hold, with a price target of $200.00. The company’s shares closed last Tuesday at $179.17, close to its 52-week low of $176.03.

According to TipRanks.com, Titchmarsh is a 2-star analyst with an average return of 0.9% and a 45.5% success rate. Titchmarsh covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for IQVIA Holdings with a $211.40 average price target, a 17.8% upside from current levels. In a report issued on June 12, TipRanks – OpenAI also downgraded the stock to Hold with a $199.00 price target.

See today’s best-performing stocks on TipRanks >>

BridgeBio Pharma (BBIO)

In a report released today, Tiago Fauth from Raymond James maintained a Buy rating on BridgeBio Pharma, with a price target of $98.00. The company’s shares closed last Tuesday at $66.64.

According to TipRanks.com, Fauth is a 4-star analyst with an average return of 11.8% and a 47.3% success rate. Fauth covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Rapport Therapeutics, Inc., and Milestone Pharmaceuticals. ;'>

Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $106.22, which is a 57.4% upside from current levels. In a report issued on June 3, Canaccord Genuity also initiated coverage with a Buy rating on the stock with a $104.00 price target.

Guardant Health (GH)

Wells Fargo analyst Brandon Couillard maintained a Buy rating on Guardant Health today and set a price target of $125.00. The company’s shares closed last Tuesday at $127.34.

According to TipRanks.com, Couillard is a 5-star analyst with an average return of 16.6% and a 61.3% success rate. Couillard covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Bio-Rad Laboratories, and GeneDx Holdings. ;'>

Currently, the analyst consensus on Guardant Health is a Strong Buy with an average price target of $143.39, representing a 10.1% upside. In a report issued on June 5, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $165.00 price target.

Read More on IQV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).